Literature DB >> 14514970

Relationship between Hodgkin's and non-Hodgkin's lymphomas.

Rose-Marie Amini1, Gunilla Enblad.   

Abstract

Malignant lymphomas have traditionally been classified as either Hodgkin's (HL) or non-Hodgkin's lymphomas (NHL). The tumor cells in NHL have been identified as being derived from T- or B-lymphocytes, but not until recently was it possible to identify the origin of the tumor cells in HL. Differential diagnostic problems may exist with morphological overlaps between HL and NHL but do not reflect an underlying biological relationship. Recent observations indicate that HL and NHL may be more closely related than previously believed. HL and NHL may occur sequentially or simultaneously in one and the same individual and in a few cases a clonal relationship between the lymphomas has been proven. It is thus possible that a biological relationship between the disorders may exist in addition to morphological overlaps, and the purpose with this review is to summarize the different relations between HL and NHL.

Entities:  

Mesh:

Year:  2003        PMID: 14514970     DOI: 10.1385/MO:20:3:211

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  63 in total

Review 1.  CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features.

Authors:  H Stein; H D Foss; H Dürkop; T Marafioti; G Delsol; K Pulford; S Pileri; B Falini
Journal:  Blood       Date:  2000-12-01       Impact factor: 22.113

2.  Hodgkin's disease following non-Hodgkin's lymphoma.

Authors:  L B Travis; C L Gonzalez; B F Hankey; E S Jaffe
Journal:  Cancer       Date:  1992-05-01       Impact factor: 6.860

3.  Down-regulation of BOB.1/OBF.1 and Oct2 in classical Hodgkin disease but not in lymphocyte predominant Hodgkin disease correlates with immunoglobulin transcription.

Authors:  H Stein; T Marafioti; H D Foss; H Laumen; M Hummel; I Anagnostopoulos; T Wirth; G Demel; B Falini
Journal:  Blood       Date:  2001-01-15       Impact factor: 22.113

4.  Epstein-Barr virus-negative Hodgkin's lymphoma after mycosis fungoides: molecular evidence for distinct clonal origin.

Authors:  M Kremer; M Sandherr; B Geist; A D Cabras; H Höfler; F Fend
Journal:  Mod Pathol       Date:  2001-02       Impact factor: 7.842

Review 5.  Interaction between host T cells and Reed-Sternberg cells in Hodgkin lymphomas.

Authors:  S Poppema; A van den Berg
Journal:  Semin Cancer Biol       Date:  2000-10       Impact factor: 15.707

6.  Classification of Hodgkin's disease biopsies by a panel of four histopathologists. Report of 1,140 patients from the German National Trial.

Authors:  A Georgii; R Fischer; K Hübner; E W Schwarze; J Bernhards
Journal:  Leuk Lymphoma       Date:  1993-03

7.  Epstein-Barr virus is infrequently identified in non-Hodgkin's lymphomas associated with Hodgkin's disease.

Authors:  D W Kingma; L J Medeiros; J Barletta; M Raffeld; R B Mann; R F Ambinder; E S Jaffe
Journal:  Am J Surg Pathol       Date:  1994-01       Impact factor: 6.394

8.  Non-Hodgkin's lymphoma arising in patients treated for Hodgkin's disease in the BNLI: a 20-year experience. British National Lymphoma Investigation.

Authors:  M H Bennett; K A MacLennan; G Vaughan Hudson; B Vaughan Hudson
Journal:  Ann Oncol       Date:  1991-02       Impact factor: 32.976

9.  Non-Hodgkin's lymphoma in an Asian population: 1968-1992 time trends and ethnic differences in Singapore.

Authors:  A Seow; J Lee; I Sng; C M Fong; H P Lee
Journal:  Cancer       Date:  1996-05-01       Impact factor: 6.860

Review 10.  The interrelationship between Hodgkin's disease and non-Hodgkin's lymphomas.

Authors:  E S Jaffe; A Zarate-Osorno; D W Kingma; M Raffeld; L J Medeiros
Journal:  Ann Oncol       Date:  1994       Impact factor: 32.976

View more
  5 in total

1.  Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype.

Authors:  Lindsay M Morton; Rochelle E Curtis; Martha S Linet; Elizabeth C Bluhm; Margaret A Tucker; Neil Caporaso; Lynn A G Ries; Joseph F Fraumeni
Journal:  J Clin Oncol       Date:  2010-10-12       Impact factor: 44.544

2.  Malignant lymphoma in Eastern India: A retrospective analysis of 455 cases according to World Health Organization classification.

Authors:  Santosh Kumar Mondal; Palash Kumar Mandal; Tarun Kumar Samanta; Subrata Chakaborty; Saptarshi Dutta Roy; Shravasti Roy
Journal:  Indian J Med Paediatr Oncol       Date:  2013-10

Review 3.  The Role of Activator Protein-1 (AP-1) Family Members in CD30-Positive Lymphomas.

Authors:  Ines Garces de Los Fayos Alonso; Huan-Chang Liang; Suzanne D Turner; Sabine Lagger; Olaf Merkel; Lukas Kenner
Journal:  Cancers (Basel)       Date:  2018-03-28       Impact factor: 6.639

4.  Activated hippo signal pathway inhibits cell proliferation and promotes apoptosis in NK/T cell lymphoma cells.

Authors:  Yu Chang; Xiao-Rui Fu; Meng Cui; Wei-Ming Li; Lei Zhang; Xin Li; Ling Li; Zhen-Chang Sun; Xu-Dong Zhang; Zhao-Ming Li; Xiao-Yan You; Fei-Fei Nan; Jing-Jing Wu; Xin-Hua Wang; Ming-Zhi Zhang
Journal:  Cancer Med       Date:  2019-05-23       Impact factor: 4.452

5.  Angiotensin II enhances the proliferation of Natural Killer/T-cell lymphoma cells via activating PI3K/Akt signaling pathway.

Authors:  Gui-Hua Zhang; Fa-An Miao; Jin-Ge Xu; Yan Zhang
Journal:  Biosci Rep       Date:  2020-10-30       Impact factor: 3.840

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.